Medicine
Ingrezza kit
Ingrezza kit is a prescription medicine containing Valbenazine for oral use, marketed by Neurocrine Biosciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15°C to 30°C (59°F to 86°F). INGREZZA SPRINKLE: Store at 20°C to 25°C…
Key facts
- Active ingredient (INN)
- Valbenazine
- Brand
- Ingrezza
- Dosage form
- Kit
- Route
- Oral
- Packs
- 1 blister pack
- Marketing authorisation holder
- Neurocrine Biosciences
- Manufacturer
- Neurocrine Biosciences
- Origin register
- US FDA, United States
- Storage
- Store at 15°C to 30°C (59°F to 86°F). INGREZZA SPRINKLE: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N07XX13 Valbenazine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 December 2018
- Identifiers
- RxCUI 1918224, 1918230, 1986329 +7DailyMed set ID 4c970164-cafb-421f-9eb5-c226ef0a3417NDC 70370-2048, 70370-2046Application NDA209241
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 1 kit in 1 blister pack | 70370-2046-1 | Neurocrine Biosciences | 18 August 2023 |
| 1 blister pack in 1 carton / 1 kit in 1 blister pack | 70370-2048-6 | Neurocrine Biosciences | 14 December 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 11 April 2017 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Valbenazine
Clinical summary
Valbenazine is a vesicular monoamine transporter 2 inhibitor indicated for the treatment of adults with - tardive dyskinesia. It is available as capsules and kits for oral use. MedsAcross supplies Valbenazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ValbenazineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- INGREZZA prescribing information (Neurocrine Biosciences) · U.S. National Library of Medicine, DailyMed
Need Ingrezza kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.